Internal Medicine, Nephrology · Clearwater, FL
NPI
1346271145
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1055 S Fort Harrison Ave
Clearwater, FL, 33756
Phone (727) 442-6245
Groups this clinician bills Medicare through
Medicare paid, 2024
$495K
6,278 services
Medicare patients, 2024
1,328
Average age 76
Drug cost, 2024
$1.5M
8,787 prescriptions
Company payments, 2025
$3,003
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Brucculeri was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 1,399 times for 718 patients. In total Michael Brucculeri billed 6,278 services in 29 codes, and Medicare paid $495K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-09.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,399 | 718 | $12.52 | $18K |
| 99232 Hospital E&M - Subsequent | Facility | 1,021 | 393 | $60.64 | $62K |
| 99214 Office E&M - Established | Office | 852 | 562 | $74.44 | $63K |
| 99215 Office E&M - Established | Office | 700 | 336 | $81.85 | $57K |
| 99233 Hospital E&M - Subsequent | Facility | 649 | 266 | $91.42 | $59K |
| 90960 ESRD Related Services (not dialysis) | Office | 384 | 62 | $260.56 | $100K |
| 99231 Hospital E&M - Subsequent | Facility | 210 | 156 | $37.93 | $7,965 |
| 99222 Hospital E&M - Initial | Facility | 209 | 184 | $96.13 | $20K |
| 90966 ESRD Related Services (not dialysis) | Office | 207 | 31 | $214.36 | $44K |
| 99213 Office E&M - Established | Office | 176 | 157 | $56.05 | $9,864 |
| 99223 Hospital E&M - Initial | Facility | 149 | 141 | $132.24 | $20K |
| 90935 Hemodialysis | Facility | 55 | 48 | $52.90 | $2,910 |
| 99204 Office E&M - New | Office | 41 | 41 | $127.34 | $5,221 |
| 90937 Hemodialysis | Facility | 31 | 20 | $73.52 | $2,279 |
| 99205 Office E&M - New | Office | 30 | 30 | $172.04 | $5,161 |
By year: 2022 $600K for 6,071 services; 2023 $513K for 5,261 services; 2024 $495K for 6,278 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Brucculeri prescribed most often to Medicare patients was Calcitriol, with 1,298 prescriptions and refills. In total Michael Brucculeri wrote 8,787 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calcitriol Generic | 1,298 | 3,435 | 417 | $28K |
| Allopurinol Generic | 624 | 1,815 | 196 | $6,831 |
| Cinacalcet Hcl Generic | 381 | 762 | 117 | $96K |
| Furosemide Generic | 350 | 904 | 141 | $1,870 |
| Nifedipine Er Nifedipine | 341 | 914 | 108 | $14K |
| Lisinopril Generic | 312 | 914 | 110 | $2,508 |
| Labetalol Hcl Generic | 289 | 735 | 92 | $9,469 |
| Amlodipine Besylate Generic | 286 | 786 | 103 | $1,993 |
| Potassium Chloride Generic | 286 | 713 | 106 | $5,855 |
| Losartan Potassium Generic | 234 | 692 | 79 | $2,616 |
| Carvedilol Generic | 213 | 592 | 84 | $2,301 |
| Bumetanide Generic | 193 | 525 | 75 | $7,763 |
| Valsartan Generic | 181 | 471 | 58 | $5,853 |
| Potassium Citrate Er Potassium Citrate | 151 | 413 | 49 | $18K |
| Spironolactone Generic | 130 | 377 | 47 | $1,128 |
Brand drugs: - claims; generic drugs: 8,133 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Brucculeri $3,003 ($3,003 in general payments such as food, travel and fees) from 14 companies. The largest payer was Fresenius USA Marketing, Inc. with $2,539.
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 5 | $2,539 |
| Novo Nordisk Inc NVO | 4 | $96.65 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 2 | $62.13 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $57.28 |
| Calliditas Therapeutics US Inc. | 1 | $53.09 |
| Aurinia Pharma U.S., Inc. AUPH | 1 | $28.62 |
| Ardelyx, Inc. ARDX | 1 | $27.43 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 1 | $26.29 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $25.41 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $23.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.